David Maginley

After the Bell, the question remains, ‘Did They Get It All?’

What feels like it should be a celebration is often a time for contemplation.

There’s a custom in cancer care: when the treatment is over, you get to ring “The Bell.” Families cheer, staff applaud, and everyone says, “You did it.”

But over the years, many patients have confided in me that they don’t feel safe, even as they ring the bell. Beneath the relief and celebration is a quieter question:

Am I really cured?

I understand that question personally. Throughout my own cancer journey, I was hesitant to use the word “cured.” Treatment may have ended, but testing continued—first frequently and eventually annually. Every time another scan or blood test approached, I became hypervigilant, preparing myself for a less-than-optimal result, to put it mildly.

Once you’ve had cancer, it becomes part of you. Even when you put it behind you and get on with living, it continues to inform your life in ways others may not see. There can be a lingering sense of waiting: When will it come back?

And, frankly, that anxiety is not entirely unfounded. Conventional scans, scopes and blood tests are extraordinarily valuable, but they have limits. Cancer may be present at a microscopic level before it can be detected by the tools we have traditionally relied upon.

That is why I am so excited about the technology we are raising money for through the QEII Ride for the Cure.

Minimal residual disease—or MRD—technology can search for traces of cancer at the microscopic level, potentially detecting evidence of disease that a scan or scope cannot yet see. It offers clinicians another way to understand what may be happening inside the body and may allow them to respond earlier and with greater precision.

Honestly, this is Star Trek stuff.

It goes beyond searching the body for a tumour large enough to appear on a scan. It looks for the faintest evidence that cancer may still be present. Just a few years ago, this kind of technology would have seemed almost unimaginable.

For patients, this is not only about better data. It is about what that data may give back: greater clarity, more informed decisions and, perhaps, a little less fear each time the next test comes around.

Maybe the bell will always hold a mixture of joy and uncertainty. Cancer changes us, and no technology can entirely remove the vulnerability of being human. But MRD technology may help patients stand on firmer ground after treatment—less suspended in that uneasy space between celebration and fear.

That is why this fundraiser matters so much to me.

I am deeply grateful to everyone who has donated, shared my page, encouraged our team or helped spread the word. You are not simply supporting a new piece of equipment. You are helping bring Nova Scotians access to technology that could change how cancer is detected, monitored and treated.

And you are helping give patients something they have long needed after the bell stops ringing: better answers to the question, “Did they get it all?”